Learning Objectives
- Describe the pathophysiological basis of diabetes, with an emphasis on the role of multiple mechanisms that lead to progressive loss in glycemic durability.
- Identify the pathophysiological and clinical rationale for using combination therapy in the management of type 2 diabetes.
- Evaluate the current understanding of cardiovascular risk in patients with diabetes, and the importance of multifactorial risk factor reduction.
- Recognize the role of the new class of agents SGLT2 inhibitors in the management of diabetes and its associated cardiometabolic abnormalities.
Chair
Dr. Shafiq Qaadri
MD, MPP
Family Physician, CME Lecturer, Medical Writer
Faculty
Dr. Bernard Zinman
CM, MD, FACP, FRCPC
Director, Leadership Sinai Centre for Diabetes
Professor of Medicine, University of Toronto
Dr. Subodh Verma
MD, PhD, FRCSC, FAHA
Division of Cardiac Surgery, St. Michael’s Hospital
Professor Surgery and Pharmacology & Toxicology, University of Toronto
Dr. Richard E Gilbert
MD, PhD, FRCPC, FRACP, FACP, FASN
Professor of Medicine, University of Toronto
Canada Research Chair in Diabetes Complications
Video Information
- Credit:No Credit Available
- Post Date:February 26, 2016
- Expiry Date:N/A
